Согласованная позиция экспертов о ведении пациентов с цереброваскулярными заболеваниями и нарушениями липидного обмена: фокус на первичную и вторичную профилактику

Согласительный документ включает в себя тезисы по клиническому ведению пациентов и интерпретации научных данных в областях, которые не могут быть охвачены клиническими рекомендациями. Документ предназначен для врачей неврологов, кардиологов, терапевтов. В нем объединены данные современных исследований относительно риска развития когнитивных нарушений и инсульта у пациентов с нарушениями липидного обмена, а также разработаны подходы и алгоритмы коррекции гипертриглицеридемии в рамках первичной и вторичной профилактики заболеваний, связанных с цереброваскулярными заболеваниями и атеросклерозом.

1. Woo HG, Heo SH, Kim EJ, et al. Atherosclerotic plaque locations may be related to different ischemic lesion patterns. BMC Neurol. 2020;20(1):1-7. doi:10.1186/S12883-020-01868-0/FIGURES/1.

2. Vasan RS, Pan S, Larson MG, et al. Arteriosclerosis, Atherosclerosis, and Cardiovascular Health: Joint Relations to the Incidence of Cardiovascular Disease. Hypertension. 2021;78(5):1232. doi:10.1161/HYPERTENSIONAHA.121.18075.

3. Lu Y, Zhu Y, Ma Y, et al. Original research: Association of subclinical atherosclerosis and cognitive decline: a community-based cross-sectional study. BMJ Open. 2022;12(5):59024. doi:10.1136/BMJOPEN-2021-059024.

4. Elendu C, Amaechi DC, Elendu TC, et al. Stroke and cognitive impairment: understanding the connection and managing symptoms. Annals of Medicine and Surgery. 2023;85(12):6057. doi:10.1097/MS9.0000000000001441.

5. Koton S, Pike JR, Johansen M, et al. Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort Study. JAMA Neurol. 2022;79(3):271. doi:10.1001/JAMANEUROL.2021.5080.

6. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37(9):2220-41. doi:10.1161/01.STR.0000237236.88823.47.

7. Guo X, Phan C, Batarseh S, et al. Risk factors and predictive markers of post-stroke cognitive decline–A mini review. Front Aging Neurosci. 2024;16:1359792. doi:10.3389/FNAGI.2024.1359792.

8. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. Journal of Clinical Investigation. 1993;92(1):141-6. doi:10.1172/jci116541.

9. Ежов М. В., Кухарчук В. В., Сергиенко И. В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. doi:10.15829/1560-4071-2023-5471.

10. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419-34. doi:10.1038/NRN.2017.48.

11. Kim SJ, Morales JM, Yaghi S, et al. Intracranial atherosclerotic disease mechanistic subtypes drive hypoperfusion patterns. J Neuroimaging. 2021;31(4):686-90. doi:10.1111/JON.12863.

12. Nam KW, Kwon HM, Jeong HY, et al. Cerebral white matter hyperintensity is associated with intracranial atherosclerosis in a healthy population. Atherosclerosis. 2017;265:179-83. doi:10.1016/J.ATHEROSCLEROSIS.2017.09.010.

13. Wolters FJ, Arfan Ikram M. Epidemiology of Vascular Dementia. Arterioscler Thromb Vasc Biol. 2019;39(8):1542-9. doi:10.1161/ATVBAHA.119.311908.

14. Балахонова Т. В., Погорелова О. А., Трипотень М. И. и др. Сокращенный протокол ультразвукового дуплексного сканирования сонных артерий в оценке доклинического атеросклероза с целью уточнения сердечно-сосудистого риска. Российский кардиологический журнал. 2019;(5):62-8. doi:10.15829/1560-4071-2019-5-62-68.

15. Балахонова Т. В., Ершова А. И., Ежов М. В. и др. Фокусированное ультразвуковое исследование сосудов. Консенсус российских экспертов. Кардиоваскулярная терапия и профилактика. 2022;21(7):3333. doi:10.15829/1728-8800-2022-3333.

16. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):90-8. doi:10.1016/J.JACC.2012.09.017.

17. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-72. doi:10.1056/NEJMOA054013.

18. RC H, CM B. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clin Chem. 2021;67(1):143-53. doi:10.1093/CLINCHEM/HVAA252.

19. Masuda D, Yamashita S. Postprandial Hyperlipidemia and Remnant Lipoproteins. J Atheroscler Thromb. 2017;24(2):95-109. doi:10.5551/JAT.RV16003.

20. Borén J, Taskinen MR, Olofsson SO, Levin M. Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med. 2013;274(1):25-40. doi:10.1111/JOIM.12071.

21. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies–a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-806. doi:10.1093/EURHEARTJ/EHAB551.

22. Rosenson RS, Davidson MH, Hirsh BJ, et al. Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2014;64(23):2525-40. doi:10.1016/J.JACC.2014.09.042.

23. Kitagami M, Yasuda R, Toma N, et al. Impact of Hypertriglyceridemia on Carotid Stenosis Progression under Normal Low-Density Lipoprotein Cholesterol Levels. Journal of Stroke and Cerebrovascular Diseases. 2017;26(8):1793-800. doi:10.1016/J.JSTROKECEREBROVASDIS.2017.04.010.

24. Raposeiras-Roubin S, Rosselló X, Oliva B, et al. Triglycerides and Residual Atherosclerotic Risk. J Am Coll Cardiol. 2021;77(24):3031. doi:10.1016/J.JACC.2021.04.059.

25. Sabayan B, Goudarzi R, Ji Y, et al. Intracranial Atherosclerosis Disease Associated With Cognitive Impairment and Dementia: Systematic Review and Meta-Analysis. J Am Heart Assoc. 2023;12(22):32506. doi:10.1161/JAHA.123.032506.

26. van den Beukel TC, Wolters FJ, Siebert U, et al. Intracranial arteriosclerosis and the risk of dementia: A population-based cohort study. Alzheimers Dement. 2024;20(2):869-79. doi:10.1002/ALZ.13496.

27. Gu X, Li Y, Chen S, et al. Association of Lipids With Ischemic and Hemorrhagic Stroke: A Prospective Cohort Study Among 267500 Chinese. Stroke. 2019;50(12):3376-84. doi:10.1161/STROKEAHA.119.026402.

28. Liu X, Yan L, Xue F. The associations of lipids and lipid ratios with stroke: A prospective cohort study. The Journal of Clinical Hypertension. 2019;21(1):127. doi:10.1111/JCH.13441.

29. Toth PP, Granowitz C, Hull M, et al. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2018;7(15). doi:10.1161/JAHA.118.008740.

30. Sultan S, Dowling M, DeVeber G, et al. Dyslipidemia in Children with Arterial Ischemic Stroke: Prevalence and Risk Factors. Pediatr Neurol. 2018;78:46. doi:10.1016/J.PEDIATRNEUROL.2017.09.019.

31. Lee H, Park JB, Hwang IC, et al. Association of four lipid components with mortality, myocardial infarction, and stroke in statin-naïve young adults: A nationwide cohort study. Eur J Prev Cardiol. 2020;27(8):870-81. doi:10.1177/2047487319898571.

32. Huang YQ, Huang JY, Liu L, et al. Relationship between triglyceride levels and ischaemic stroke in elderly hypertensive patients. Postgrad Med J. 2020;96(1133):128-33. doi:10.1136/POSTGRADMEDJ-2019-136961.

33. Rosenson RS, Shott S, Lu L, Tangney CC. Hypertriglyceridemia and other factors associated with plasma viscosity. Am J Med. 2001;110(6):488-92. doi:10.1016/S0002-9343(01)00643-X.

34. Castillo-Núñez Y, Morales-Villegas E, Aguilar-Salinas CA, et al. Triglyceride-Rich Lipoproteins: Their Role in Atherosclerosis. Revista de investigación clínica. 2022;74(2):61-70. doi:10.24875/RIC.21000416.

35. Nordestgaard LT, Christoffersen M, Afzal S, et al. Triglycerides as a Shared Risk Factor between Dementia and Atherosclerotic Cardiovascular Disease: A Study of 125 727 Individuals. Clin Chem. 2021;67(1):245-55. doi:10.1093/CLINCHEM/HVAA269.

36. Dimache AM, Șalaru DL, Sascău R, Stătescu C. The role of high triglycerides level in predicting cognitive impairment: A review of current evidence. Nutrients. 2021;13(6). doi:10.3390/NU13062118.

37. Nägga K, Gustavsson AM, Stomrud E, et al. Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later. Neurology. 2018;90(1):e73. doi:10.1212/WNL.0000000000004749.

38. Parthasarathy V, Frazier DT, Bettcher BM, et al. Triglycerides are Negatively Correlated with Cognitive Function in Non-demented Aging Adults. Neuropsychology. 2017;31(6):682. doi:10.1037/NEU0000335.

39. Zhou Z, Ryan J, Tonkin AM, et al. Association between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults: A Prospective Cohort Study. Neurology. 2023;101(22): E2288-E2299. doi:10.1212/WNL.0000000000207923.

40. Cheng YC, Kuo, YC, Chang, PC, et al. Geriatric Functional Impairment Using the Integrated Care for Older People (ICOPE) Approach in Community-Dwelling Elderly and Its Association with Dyslipidemia. Vascular Health and Risk Management. 2021;17:389-94. doi:10.2147/VHRM.S305490.

41. Jin L, Hua H, Ji Y, et al. Anti-inflammatory role of fenofibrate in treating diseases. Biomol Biomed. 2023;23(3):376-91. doi:10.17305/bb.2022.8534.

42. Dugan B, Conway J, Duggal NA. Inflammaging as a target for healthy ageing. Age and Ageing. 2023;52(2):afac328. doi:10.1093/ageing/afac328.

43. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960-93. doi:10.1016/J.JACC.2021.06.011.

44. Koneru SC. Fellow’s voice: Hypertriglyceridemia: Understanding the current guideline. Am J Prev Cardiol. 2022;9:100322. doi:10.1016/J.AJPC.2022.100322.

45. Mora-Rodriguez R, Ortega JF, Morales-Palomo F, et al. Effects of statin therapy and exercise on postprandial triglycerides in overweight individuals with hypercholesterolaemia. Br J Clin Pharmacol. 2020;86(6):1089-99. doi:10.1111/BCP.14217.

46. Fan W, Philip S, Granowitz C, et al. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey. J Clin Lipidol. 2019;13(1):100-8. doi:10.1016/J.JACL.2018.11.008.

47. Toth PP, Philip S, Hull M, Granowitz C. Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200-499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients. Vasc Health Risk Manag. 2019;15:533-8. doi:10.2147/VHRM.S221289.

48. Toth PP, Philip S, Hull M, Granowitz C. Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. Mayo Clin Proc. 2019;94(9):1670-80. doi:10.1016/J.MAYOCP.2019.03.028.

49. Tattersall MC, Hansen SL, McClelland RL, et al. Importance of Age and Sex in Carotid Artery Plaque Detection and Cardiovascular Disease Risk. JAMA Cardiol. Published online March 05, 2025. doi:10.1001/jamacardio.2024.5702.

50. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345. doi:10.1093/EURHEARTJ/EHR112.

51. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia. Diabetes Care. 2002;25(7):1198-202. doi:10.2337/diacare.25.7.1198.

52. Koh K, Quon M, Han S, et al. Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia. JACC. 2005;45(10):1649-53. doi:10.1016/j.jacc.2005.02.052.

53. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95(4):462-8. doi:10.1016/j.amjcard.2004.10.012. Erratum in: Am J Cardiol. 2006;98(3):427-8.

54. Group TAS. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362(17):1563. doi:10.1056/NEJMOA1001282.

55. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-61. doi:10.1016/S0140-6736(05)67667-2.

56. Irfan A, Haider SH, Nasir A, et al. Assessing the Efficacy of Omega-3 Fatty Acids + Statins vs. Statins Only on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of 40,991 Patients. Curr Probl Cardiol. 2024;49(2):102245. doi:10.1016/j.cpcardiol.2023.102245.